# nature portfolio

Corresponding author(s):	John C. Chaput
Last updated by author(s):	Mar 24, 2023

## **Reporting Summary**

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

~ .				
51	ta:	t١	c†	$I \cap S$

n/a	Confirmed
	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
x	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
	X A description of all covariates tested
×	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
x	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
x	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
x	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
×	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i> ), indicating how they were calculated
	Our was collection as statistics for high sister contains actions as many of the points where

### Software and code

Policy information about availability of computer code

Data collection

No electronic data collection was performed. PAGE gels were quantified using Image Studio Lite (LI-COR) and agarose gels were quantified using GelDoc MP imaging system (Bio-Rad). ELISA assay was quantified using Clariostar Plus microplate reader (BMG Labtech).

Data analysis

Observed rate constants were obtained by fitting the percentage of cleaved substrate over the reaction time to the one-phase association equation 2 using Prism 9 (Graphpad, USA). Microsoft Excel Pro 2010 ver 14.9.4760.1000 (32-bit) and Graphpad Prism ver 9.5.0 (730) were used to generate bar graphs and analysis data from in vitro and cellular assays.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

#### Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The authors declare that the data supporting the findings of this study are available within the article and its supplementary information file. Structural information

		e Protein Data Bank under accession code 7PDU. The raw data generated in this study are provided in the Supplementary		
Information/Source	Data file			
Human rese	earch par	ticipants		
	·	involving human research participants and Sex and Gender in Research.		
Reporting on sex a	and gender	N/A		
		N/A		
		N/A		
Ethics oversight		N/A		
lote that full inform	nation on the ap	proval of the study protocol must also be provided in the manuscript.		
		eporting  is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.		
		·		
<b>x</b> Life sciences		Behavioural & social sciences		
or a reference copy of	the document wi	th all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>		
_ife scie	nces st	udy design		
All studies must d	sclose on the	e points even when the disclosure is negative.		
Sample size	No sample si triplicate	ple size calculations were performed. Samples sizes were determined using sample sizes standard in DNAzyme research (duplicate or te		
Data exclusions	_	the revision, the data shown Figures 2c and supplementary Figures 16A (previously supplementary Figure 15A) were replaced in their for consistency.		
Replication	successful. So	ntitative measures presented in the main text figures were replicated in duplicate or triplicate. All attempts at replication were ful. Screening of DNAzymes performed in SI figures were not replicated, but the findings in these figures are supported by replicate esented in the main text figures.		
Randomization	the same pas	ization was not performed. Cells transfected with or without DNAzyme were seeded at the same time using a single batch of cells of e passage number and underwent experimentation in parallel. In each experimental replicate, the same incubator, culture plate, and transfection reagents were used.		
Blinding	_	ng was not used in these studies. Blinding was not necessary as all quantitative measurements were carried out unbiasedly using Gel tification software.		
•		pecific materials, systems and methods		
		es about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.		
Materials & ex	kperimental	systems Methods		
n/a Involved in t				
THE PROPERTY OF THE PROPERTY O	_	**      Cim 309		

Materials & experimental systems	Methods	
n/a Involved in the study	n/a Involved in the study	
X Antibodies	ChIP-seq	
Eukaryotic cell lines	Flow cytometry	
Palaeontology and archaeology	MRI-based neuroimaging	
X Animals and other organisms		
X Clinical data		
Dual use research of concern		

## Eukaryotic cell lines

Policy information about <u>cell lines and Sex and Gender in Research</u>

Cell line source(s) HEK293, K562, and NCI-H441 cell lines were purchased from ATCC.

Authentication The morphology of each cell lines was similar to the corresponding reference cell line at ATCC

Mycoplasma contamination All cell lines tested negative for mycoplasma contamination

Commonly misidentified lines (See <u>ICLAC</u> register)

None of the cell lines used were commonly misidentified